Schizophrenia remains a major health burden, highlighting the need for new treatment
approaches. We consider the potential for targeting the trace amine (TA) system. We first …

Ulotaront is a trace amine-associated receptor 1 (TAAR1) agonist in Phase 3 clinical
development for the treatment of schizophrenia. Ulotaront was discovered through a unique …

Trace amine-associated receptor 1 (TAAR1), the founding member of a nine-member family
of trace amine receptors, is responsible for recognizing a range of biogenic amines in the …

Abstract Background and Hypothesis Type-1 trace amine-associated receptors (TAAR1)
modulate dopaminergic and glutamatergic neurotransmission and are targeted by novel …

Patients with schizophrenia experience a broad range of detrimental health outcomes
resulting from illness severity, heterogeneity of disease, lifestyle behaviors, and adverse …

Aberrant dopaminergic and glutamatergic function, particularly within the striatum and
hippocampus, has repeatedly been associated with the pathophysiology of schizophrenia …

Background Trace amine-associated receptor-1 (TAAR1) agonists have been proposed as
potential antipsychotics, with ulotaront and ralmitaront having reached clinical trials. While …

Abstract Background Metabolic syndrome (MetS), which can be induced or exacerbated by
the current class of antipsychotic drugs, is highly prevalent in patients with schizophrenia …

All antipsychotics currently used in clinic block D2 dopamine receptors. Trace amine-
associated receptor 1 is emerging as a new therapeutic target for schizophrenia and several …

Introduction: Schizophrenia is a serious mental illness that requires effective treatment with
minimal adverse effects. As preclinical and clinical research progresses, trace amine …